Literature DB >> 19808227

Renal function in glycogen storage disease type I, natural course, and renopreservative effects of ACE inhibition.

Daniëlle H J Martens1, Jan Peter Rake, Gerjan Navis, Vaclav Fidler, Catharina M L van Dael, G Peter A Smit.   

Abstract

BACKGROUND AND OBJECTIVES: Renal failure is a major complication in glycogen storage disease type I (GSD I). We studied the natural course of renal function in GSD I patients. We studied differences between patients in optimal and nonoptimal metabolic control and possible renoprotective effects of angiotensin converting enzyme inhibition. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Thirty-nine GSD I patients that visited our clinic were studied. GFR and effective renal plasma flow (ERPF) were measured by means of I(125) iothalamate and I(131) hippuran clearance and corrected for body surface area. Microalbuminuria was defined as >2.5 mg albumin/mmol creatinine and proteinuria as >0.2 g protein per liter. Optimal metabolic control was present when blood glucoses were >3.5 mmol/L, urine lactate/creatinine ratios <0.06 mmol/mmol, triglycerides <6.0 mmol/L, and uric acid concentrations <450 micromol/L.
RESULTS: Quadratic regression analysis showed a biphasic pattern in the course of GFR and ERPF related to age. Microalbuminuria was observed significantly less frequently in the patients with optimal metabolic control compared with the patients with nonoptimal metabolic control. A significant decrease in GFR was observed after starting ACE inhibition.
CONCLUSIONS: This study describes a biphasic pattern of the natural course of GFR and ERPF in GSD I patients, followed by the development of microalbuminuria and proteinuria. Optimal metabolic control has a renoprotective effect on the development of microalbuminuria and proteinuria in GSD I patients. Treatment with ACE inhibitors significantly decreases the GFR, especially in GSD I patients with glomerular hyperfiltration.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19808227      PMCID: PMC2774963          DOI: 10.2215/CJN.00050109

Source DB:  PubMed          Journal:  Clin J Am Soc Nephrol        ISSN: 1555-9041            Impact factor:   8.237


  20 in total

1.  Glycogen storage disease type I: diagnosis, management, clinical course and outcome. Results of the European Study on Glycogen Storage Disease Type I (ESGSD I).

Authors:  Jan Peter Rake; Gepke Visser; Philippe Labrune; James V Leonard; Kurt Ullrich; G Peter A Smit
Journal:  Eur J Pediatr       Date:  2002-08-22       Impact factor: 3.183

2.  Hyperfiltration and renal disease in glycogen storage disease, type I.

Authors:  L Baker; S Dahlem; S Goldfarb; E F Kern; C A Stanley; J Egler; J S Olshan; S Heyman
Journal:  Kidney Int       Date:  1989-06       Impact factor: 10.612

Review 3.  Guidelines for management of glycogen storage disease type I - European Study on Glycogen Storage Disease Type I (ESGSD I).

Authors:  Jan Peter Rake; Gepke Visser; Philippe Labrune; James V Leonard; Kurt Ullrich; G Peter A Smit
Journal:  Eur J Pediatr       Date:  2002-08-24       Impact factor: 3.183

4.  Is glycogen storage disease 1a associated with atherosclerosis?

Authors:  Froukje L Ubels; Jan Peter Rake; Joris P J Slaets; G Peter A Smit; Andries J Smit
Journal:  Eur J Pediatr       Date:  2002-07-02       Impact factor: 3.183

Review 5.  Type I glycogen storage disease: kidney involvement, pathogenesis and its treatment.

Authors:  Y T Chen
Journal:  Pediatr Nephrol       Date:  1991-01       Impact factor: 3.714

Review 6.  Diabetic nephropathy.

Authors:  H A Ibrahim; J P Vora
Journal:  Baillieres Best Pract Res Clin Endocrinol Metab       Date:  1999-07

7.  Glycogenosis type I and diabetes mellitus: a common mechanism for renal dysfunction?

Authors:  H R Mundy; P J Lee
Journal:  Med Hypotheses       Date:  2002-07       Impact factor: 1.538

8.  Renal glomerular and tubular abnormalities in glycogen storage disease type I.

Authors:  R Verani; J Bernstein
Journal:  Arch Pathol Lab Med       Date:  1988-03       Impact factor: 5.534

9.  Renal disease in type I glycogen storage disease.

Authors:  Y T Chen; R A Coleman; J I Scheinman; P C Kolbeck; J B Sidbury
Journal:  N Engl J Med       Date:  1988-01-07       Impact factor: 91.245

10.  Revisiting normal (51)Cr-ethylenediaminetetraacetic acid clearance values in children.

Authors:  A Piepsz; M Tondeur; H Ham
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-07-25       Impact factor: 10.057

View more
  17 in total

Review 1.  Glycogen storage disease type I and G6Pase-β deficiency: etiology and therapy.

Authors:  Janice Y Chou; Hyun Sik Jun; Brian C Mansfield
Journal:  Nat Rev Endocrinol       Date:  2010-10-26       Impact factor: 43.330

2.  Tight metabolic control plus ACE inhibitor therapy improves GSD I nephropathy.

Authors:  Gyongyi O Okechuku; Lawrence R Shoemaker; Monika Dambska; Laurie M Brown; Justin Mathew; David A Weinstein
Journal:  J Inherit Metab Dis       Date:  2017-06-13       Impact factor: 4.982

3.  Hepatorenal correction in murine glycogen storage disease type I with a double-stranded adeno-associated virus vector.

Authors:  Xiaoyan Luo; Gentzon Hall; Songtao Li; Andrew Bird; Peter J Lavin; Michelle P Winn; Alex R Kemper; Talmage T Brown; Dwight D Koeberl
Journal:  Mol Ther       Date:  2011-07-05       Impact factor: 11.454

4.  Targeted deletion of kidney glucose-6 phosphatase leads to nephropathy.

Authors:  Julie Clar; Blandine Gri; Julien Calderaro; Marie-Christine Birling; Yann Hérault; G Peter A Smit; Gilles Mithieux; Fabienne Rajas
Journal:  Kidney Int       Date:  2014-04-09       Impact factor: 10.612

Review 5.  Lessons from new mouse models of glycogen storage disease type 1a in relation to the time course and organ specificity of the disease.

Authors:  Fabienne Rajas; Julie Clar; Amandine Gautier-Stein; Gilles Mithieux
Journal:  J Inherit Metab Dis       Date:  2014-08-28       Impact factor: 4.982

Review 6.  Polycystic kidney features of the renal pathology in glycogen storage disease type I: possible evolution to renal neoplasia.

Authors:  Monika Gjorgjieva; Laure Monteillet; Julien Calderaro; Gilles Mithieux; Fabienne Rajas
Journal:  J Inherit Metab Dis       Date:  2018-06-04       Impact factor: 4.982

7.  Aggressive therapy improves cirrhosis in glycogen storage disease type IX.

Authors:  Laurie A Tsilianidis; Laurie M Fiske; Sara Siegel; Chris Lumpkin; Kate Hoyt; Melissa Wasserstein; David A Weinstein
Journal:  Mol Genet Metab       Date:  2013-03-21       Impact factor: 4.797

Review 8.  Liver transplantation in glycogen storage disease type I.

Authors:  Susanna J B Boers; Gepke Visser; Peter G P A Smit; Sabine A Fuchs
Journal:  Orphanet J Rare Dis       Date:  2014-04-09       Impact factor: 4.123

9.  Bone mineral density in glycogen storage disease type Ia and Ib.

Authors:  Laurie A Minarich; Alexander Kirpich; Laurie M Fiske; David A Weinstein
Journal:  Genet Med       Date:  2012-04-05       Impact factor: 8.822

10.  Glycogen and the propensity for atrial fibrillation: intrinsic anatomic differences in glycogen in the left and right atria in the goat heart.

Authors:  Abraham A Embi; Benjamin J Scherlag; Jerry W Ritchey
Journal:  N Am J Med Sci       Date:  2014-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.